The continuing research into CFTR modulators has answered many questions but has raised many others. Such as:
Is there a single specific algorithm applicable to newborn CF screening in the US?
How well have expanded variant panels improved CF detection in non-white and Hispanic newborns?
How young is too young to initiate CFTR modulator therapy?
How rare is it for CF to be diagnosed in adulthood?
Has CFTR modulator therapy been shown to be effective in older patients?
Join us as our expert faculty from the Johns Hopkins School of Medicine discusses these and other issues affecting CF treatment and patient outcomes … in this special issue of eCysticFibrosis Review.
Describe emerging newborn screening approaches to enhance early detection of CF across diverse populations.
Explain diagnostic strategies for recognizing CF in adults, including atypical and late-diagnosed cases.
Assistant Professor of Pediatrics
Johns Hopkins University School of Medicine
Baltimore, MD
Menowitz/Rosenstein Professor of Pediatric Respiratory Sciences
Director, Eudowood Division of Pediatric Respiratory Sciences
Director, Cystic Fibrosis Center
Johns Hopkins School of Medicine
Baltimore, MD
Menowitz/Rosenstein Professor of Pediatric Respiratory Sciences
Director, Eudowood Division of Pediatric Respiratory Sciences
Director, Cystic Fibrosis Center
Johns Hopkins School of Medicine
Baltimore, MD
Senior Clinical Nurse/Case Manager
Pediatric CF Program Coordinator
Johns Hopkins Cystic Fibrosis Center
Baltimore, MD
0.5 hour Physicians
0.5 contact hour Nurses
Launch date: October 7, 2026
Expiration date: October 6, 2028